GSK Touts Positive Phase 3 Data for Anemia-Linked CKD Drug

GlaxoSmithKline’s (GSK) daprodustat increased or maintained hemoglobin levels in patients with anemia due to chronic kidney disease (CKD) across five phase 3 studies, says a new analysis.
Source: Drug Industry Daily